Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)

Model scores of the 29,894 trials active now.

Model score 25% for any early termination, 21% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (446 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-10-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientcancerstudy isbrainto use
  Phrases that lowered it: participantsevaluate theto evaluatebleedingheparin
• Sponsor's past termination rate: 14.8% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor's past trials: 823 (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 13.1% (lowers risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 205 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: 73.3% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Drug's FAERS reports in the prior 12 months: 21425 (lowers risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism NCT02585713 · started 2015 · scored riskier than 59% of active trials completed
• Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy NCT03080883 · started 2017 · scored riskier than 60% of active trials completed
• A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE NCT05171049 · started 2022 · scored riskier than 43% of active trials terminated
• API-CAT STUDY for APIxaban Cancer Associated Thrombosis NCT03692065 · started 2018 · scored riskier than 74% of active trials completed
• Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra NCT02270918 · started 2014 · scored riskier than 4% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.